It is now about 40 years since Avram Goldstein proposed the use of the stereoselectivity of opioid receptors to identify these receptors in neural membranes. In 2012, the crystal structures of the four members of the opioid receptor family were reported, providing a structural basis for understanding of critical features affecting the actions of opiate drugs. This minireview summarizes these recent developments in our understanding of opiate receptors. Receptor function is also influenced by amino acid substitutions in the protein sequence. Among opioid receptor genes, one polymorphism is much more frequent in human populations than the many others that have been found, but the functional significance of this single nucleotide polymorphism (SNP) has been unclear. Recent studies have shed new light on how this SNP might influence opioid receptor function. In this minireview, the functional significance of the most prevalent genetic polymorphism among the opioid receptor genes is also considered.
Introduction
Avram Goldstein was already an established investigator when he became interested in the actions of opiate drugs in the late 1960s. An early goal was the identification and characterization of the opiate receptor (then always referred to in the singular). This required a reliable assay. Avram's strategy was to use two criteria, the well defined stereoselectivity of the opioid receptor (known as opioid peptide receptors; OPr) and the sensitivity of opiate analgesic action to antagonism by naloxone, to identify that component of total binding of the radiolabeled opiate that represented binding to the receptor (Goldstein et al., 1971) . In this initial study, the fraction of opiate binding attributable to the receptor was rather small, but the same basic strategy was used later, together with opiate ligands with much higher radiochemical specific activity and a more efficient method of elimination of nonspecific binding, by Lars Terenius and the Snyder and Simon groups (Pert and Snyder, 1973; Terenius, 1973; Simon et al., 1973) to show the presence in the brain and gastrointestinal tract of binding proteins with high specificity for opiate drugs. This unambiguous demonstration of the binding to OPrs from three independent laboratories triggered continuing studies of the properties of these receptors, and also the search for an endogenous agent (again always discussed in the singular at this time) that was presumed to be the physiologic regulator of the opiate drug receptor. This minireview summarizes recent developments in our understanding of opiate receptors following the publication in 2012 of the crystal structures of all four members of the OPr family, and recent studies evaluating the role in m-OPr (MOPr) function of the most prevalent genetic polymorphism among the OPr genes.
provide a number of insights into the actions of opiate drugs, and a few surprises. A comparison of the major features of the reported crystal structures of the four receptors making up the OPr family is contained in Table 1 .
Achieving crystallization of these GPCRs is a major technological achievement. It required substantial molecular engineering of the receptors during which highly disordered regions of the receptor were replaced with fragments of another protein known to assist in structural stabilization; residues 2-161 of T4 lysozyme were inserted into the third intracellular loop (ICL) of the OPrs to facilitate their crystallization. The highly flexible N-and C-terminal regions of the wild-type receptor protein sequences were also truncated to aid crystallization, and a FLAG tag and a poly-His sequence with cleavage sites were inserted on the truncated N terminus or the truncated C terminus, respectively, to aid purification of the expressed engineered receptors. Despite this extensive engineering, each receptor when expressed in cells in culture retained the ability to bind highly selective ligands with only modest changes in affinity and was capable   TABLE 1 Comparison of the reported crystal structures for the four OPrs complexed with antagonist drugs Specific amino acids are indicated by their single-letter amino acid code, with numbers indicating their position in the receptor sequence; numbers in parentheses indicate their position within the TM a-helices (using the Ballesteros-Weinstein nomenclature); e.g., H297(6.52) indicates a His residue in sequence position 297, located in the sixth TM a-helix at position 52 within the helix; position 52 refers to the residue location relative to the most conserved amino acid within the helix, which is arbitrarily given the locator 50, so that position 52 is 2 residues toward the C terminus from the most conserved amino acid; a position number of ,50 indicates a location toward the N terminus relative to the most conserved amino acid. Note the conservation across the receptor types of the positions within the a-helix structure of amino acid residues critical for ligand binding; e.g., D147(3.32), D128(3.32), D138(3.32), and D130(3.32) of supporting agonist-induced changes in signal transduction pathways.
Antagonist Ligands in the Receptor Complexes
To further aid in the crystallization process, each receptor was bound to a tightly binding selective antagonist drug. The irreversible selective ligand b-funaltrexamine (b-FNA) was bound to the MOPr ; a covalent link between b-FNA and the «-amino group of a lysine (K233) residue in the fifth transmembane (TM) domain of MOPr was identified. The DOPr was crystallized in complex with the high-affinity DOPr-selective reversible antagonist naltrindole . The engineered human KOPr was crystallized in complex with the high-affinity KOPr-selective , while the engineered human NOPr was crystallized in complex with the novel high-affinity NOPr-selective antagonist 1-benzyl-N-{3-[spiroisobenzofuran-1(3H),49-piperidin-1-yl]propyl} pyrrolidine-2-carboxamide (C-24), from Banyu Pharmaceutical (Tokyo, Japan) . The C-24 structure is analogous to the first four amino acid residues of the endogenous ligand, nociceptin/orphanin FQ; C-24 has a Ki of 0.3 nM for the wild-type receptor and about 2 nM for the engineered NOPr. The use of antagonists as the cocrystallized ligands facilitates the formation of crystals by freezing the receptors in their relatively stable inactive conformations.
TM Domains
Each receptor has seven a-helical TM domains (7TM) that are aligned around a central ligand-binding pocket as anticipated from earlier studies comparing analogous sequences in rhodopsin with the OPr sequences, and considering the placement of the a-helical TM domains of rhodopsin. There appears to be considerable similarity in the overall orientation of the 7TM helices between the four members of the OPr family, although the spatial alignment of NOPr differs in places from the more conserved orientations of the MOPr, DOPr, and KOPr TM domains . All four receptors have bends in some of the TM helices (TM2, TM4, TM5, TM6, and TM7) induced by the presence Pro residues roughly centered in each TM domain (Thompson et al., 2102) . These Pro residues are highly conserved across most GPCRs; their presence is emphasized in the description of the crystal structure of the b 2 -adrenergic receptor (b 2 -AR), the first GPCR to be crystallized (Cherezov et al., 2007) . The bends in the TM domains contribute to the shape of the ligand-binding pocket for each receptor. In contrast to the conserved TM domains, the extracellular loops (ECLs) and the ICLs show more extensive variation between members of the OPr family. The ECL2 domains of KOPr and NOPr differ from those of MOPr and DOPr by the increased frequency of acidic amino acid residues (Asp, Glu), making the entrance to the ligand-binding pocket in these receptors highly acidic . This may be related to the highly basic nature of dynorphin A and nociceptin/orphanin FQ, the endogenous ligands for KOPr and NOPr, respectively. The overall structure of GPCRs is also supported by the presence of one or more conserved Cys-Cys bonds. In the OPr family there is just one conserved Cys-Cys disulfide bond in a similar location in each receptor, linking the second extracellular loop (ECL2) to the intracellular end of TM3.
Ligand-Binding Pocket
There are also many similarities in the binding pockets of the OPrs (Fig. 1) . In all cases, the binding pocket is located in the center of the receptors, deep within the hollow created by the encircling TM domain regions. The pocket appears more open to the extracellular fluid than is reported for the binding pockets of other GPCRs with small-molecule endogenous ligands. Manglik et al. (2012) suggest that the open nature of the OPr ligand-binding pocket is consistent with the very short dissociation half-lives of highly potent MOPr antagonists; for example, diprenorphine (Ki, 72 pM) has a dissociation half-life of 36 minutes from MOPr. In contrast, the M 3 muscarinic receptor structure displays a much more restricted entry to its ligand-binding site, and the potent M 3 receptor antagonist tiotropium (Ki, 40 pM), has a dissociation half-life of about 35 hours. The amino acid residues within the OPr binding pocket with which the very-high-affinity highly selective antagonists used in these studies interact are in part specific to the unique characteristics of these very specialized ligands. Nevertheless, several similarities across the receptor types are apparent. Conserved Asp residues [D147(3.32), D128(3.32), D138(3.32), and D130(3.32) in MOPr, DOPr, KOPr, and NOPr, respectively] are located in essentially the same location within the third TM helix of each receptor (Fig. 1) . Mutation of this Asp residue in each receptor to a noncharged alternative amino acid results in loss of opioid activity. The Asp residue is thought to form a charge-charge interaction with a positively charged group in the ligands binding to each receptor. It has long been assumed than an ionic interaction between the ligand and each OPr is a critical feature in the binding of opiate ligands to their receptors (Beckett and Casy, 1954) . The structural basis for this is now apparent. Another common feature of the binding site is the presence of a conserved His residue in three of the four OPrs [H297(6.52), H278(6.52), and H291(6.52) in MOPr, DOPr, and KOPr, respectively]. In NOPr, this His is replaced by a Gln [Q280(6.52)]. The His residues in the three "classic" OPrs are thought to interact by hydrogen bonding through two associated water molecules with the tyrosine-like hydroxyl moieties of the morphinan ligands . There are a number of other amino acids located in close contact with the docked antagonist molecules in these receptors ( Fig. 1 ; Table 1 ). Some of these interactions are probably specific for the unique high-affinity antagonist ligands selected for the crystallization, but many may also be important in the docking and agonist action of physiologic agonists. It should be noted that the Lys residue [K233(5.39)] covalently linked to the b-FNA in the MOPr crystal is likely to be a special case resulting from the covalent nature of this interaction.
Receptor Oligomerization
The MOPr and KOPr crystals formed as parallel dimers tightly associated through TM5 and TM6, and to a lesser extent between TM1 and TM2, although in the KOPr crystal antiparallel dimers were also observed. In contrast, DOPr was reported to crystallize exclusively as antiparallel dimers . The antiparallel form appears unlikely in biologic membranes; the authors argue that the antiparallel arrangement may reflect an energetically favorable arrangement during the crystallization process with naltrindole. It is highly unlikely that the antiparallel arrangement is a reflection of intermolecular associations that occur in vivo (this would require that the binding pocket of one of the receptors in the dimer faced the interior of the cell). The presence of parallel dimers in MOPr and KOPr crystals provides a structural basis for earlier studies reporting the homoand heterodimerization of OPrs in biologic membranes (Cvejic and Devi, 1997; Jordan and Devi, 1999; George et al., 2000) . It should be noted that the observed dimerization in the crystals occurs during crystallization-the engineered receptors were purified as monomers-so there is no certainty that the oligomerization forms found in the crystal represent functional dimer forms present in vivo.
The role of membrane cholesterol in determining the preferred structures of GPCRs and in modulating OPr function also requires consideration. Cholesterol was used to facilitate the crystallization of b 2 -AR bound to an antagonist (Cherezov et al., 2007) and when this GPCR was cocrystallized together with G s in the presence of a b 2 -AR agonist (Rasmussen et al., 2011) . Cherezov et al. (2007) reported that cholesterol mediates the parallel association of dimers in b 2 -AR crystals, raising the possibility that it plays a similar role in facilitating dimer formation in vivo. Crystallization of the four OPrs also required the presence of cholesterol Manglik et al., 2012; Thompson et al., 2012; Wu et al., 2012) , although the role of cholesterol as a factor determining the observed structures of these receptors is not discussed by the authors. It has long been known that modulating the cholesterol content of OPr-expressing cell membranes can alter the binding and signal transduction properties of the receptors (Lazar and Medzihradsky, 1992; Xu et al., 2006; Gaibelet et al., 2008; Zheng et al., 2012) , although the authors differ in their proposed (non-mutually exclusive) mechanisms (e.g., altered membrane microviscosity, receptor partition into lipid rafts, facilitation of association with G proteins, facilitation of dimer formation, modulation of receptor palmitoylation).
Agonism at Opioid Receptors
The elucidation of the crystal structure of all members of the OPr family provides a strong basis for design of selective ligands for each receptor, but the antagonist-bound crystal structures shed less light on the changes in receptor structure and conformation that result in the induction of agonist effects. Like other GPCRs, most of the observed actions of OPr ligands require the activation of a G protein to trigger further downstream events within a cell. OPrs predominantly couple with G i or G o to cause dissociation of the Gabg complex and trigger downstream cellular processes. Recently, the Kobilka laboratory reported the crystallization of the b 2 -AR complexed with the G s a-subunit (Rasmussen et al., 2011) , another extraordinary technical achievement requiring crystallization conditions that maintain the association of an agonistbound receptor with the G-protein heterotrimer. The agonist form of the b 2 -AR with G s indicates that agonism requires substantial changes in the orientation of b 2 -AR-complexed microdomains within the G s a-subunit. To date there is no report of the crystallization of an OPr or any other G i/ocoupled GPCR in complex with the G i/o a-subunit. The Rasmussen et al. (2011) study indicates a pathway toward crystallization of an agonist-form OPr crystal, but many technical challenges will need to be overcome to achieve this. It remains to be determined if G i and/or G o activation results from a reorientation of the C termini of these proteins that is analogous to the agonist-activated b 2 -AR-mediated reorientation of the G s a-subunit C terminus.
Opioid Receptor Polymorphisms and Receptor Function
The primary sequence of a GPCR is a major determinant of the secondary and tertiary structure of the mature receptor. It is therefore possible that polymorphisms in an OPr gene might result in the expression of a receptor with a modified tertiary structure and altered functional activity. There are numerous single nucleotide polymorphisms (SNPs) in the human MOPr gene, but most are rare and their functional significance, if any, is unknown (see review by Mague and Blendy, 2010) . At this time, a polymorphism in an OPr gene that alters the major conformation of the expressed receptor has not been reported. In the MOPr gene, one SNP (rs 1799971) occurs relatively frequently in some human populations. The polymorphism is located in exon 1, where a change in adenosine (A) to guanosine (G) in nucleotide position 118 (A118G) results in a change in amino acid sequence in which Asn40 in replaced by Asp (designated N40D). This SNP has now been studied more extensively than the other SNPs in MOPr or any SNPs in the other OPrs. A118G occurs with variable frequency in different human populations, with the highest reported allelic frequency of 118G being 48.5% in a Japanese population. In contrast, the 118G allelic frequency is 15.4% in European-Americans, 14% in Hispanics, 8% in Bedouins, and 5% in African Americans (Gelernter et al., 1999) ; other studies show approximately similar relative distributions by population and confirm the high expression of this SNP in Asian populations (Bond et al., 1998; Tan et al., 2009) . Initial reports suggested that this SNP was associated with addictive behaviors for several drugs, but more extensive studies have not confirmed this apparent association, and the effect of the A118G polymorphism has been variously reported to be either an increase or a reduction in the risk of substance abuse. There is more consistent agreement that A118G is associated with impaired opioid signaling through MOPr and a need for increased opiate drug doses in patients with the G variant in a variety of painful conditions (see review by Mague and Blendy, 2010) .
The N40D (A118G) mutation occurs in the N-terminal extracellular domain of MOPr, a part of the receptor that is highly disordered. Manglik et al. (2012) removed this extracellular domain in their engineered receptor to facilitate its crystallization. It is therefore unlikely that this SNP alters the basic threedimensional structure of the MOPr protein. Early reports suggested that A118G resulted in increased signaling through MOPr by the endogenous ligand b-endorphin (Bond et al., 1998) , but more recent studies found unchanged opioid ligand binding with impaired opioid signaling in the 118G variant (Mague and Blendy, 2010; Oertel et al., 2012) . Kroslak et al. (2007) reported that 118G reduced the level of MOPr protein (observed as reduced ligand B max for opioid ligands) and found a lower potency of opiates as inhibitors of adenylyl cyclase in oocytes transfected with this receptor variant. To evaluate the function of this receptor more fully, Mague et al. (2009) generated a mouse analog with nucleotide A112 of the mouse MOPr gene mutated to a G (A112G), resulting in conversion of Asn38 to Asp38 (N38D; corresponding to N40D in the human gene). The mutated mouse receptor displayed essentially unchanged ligand-binding affinities for several ligands, but reduced levels of receptor mRNA and protein expression were observed in most brain regions, suggesting that a reduction in the number of receptors may account for the impaired signaling. One effect of the N40D change is the loss of an N-glycosylation site on the N terminus of the receptor protein. Huang et al. (2012) have confirmed that the N38D (A112G) receptor shows reduced glycosylation in homozygous A112G mice and that the reduced glycosylation is associated with a reduction in the stability of the modified receptor. Thus, one potential explanation of the reduced level of receptor expression is a reduced stability of the less glycosylated MOPr protein.
Other factors also contribute to the reduced levels of receptor protein in those carrying the A118G mutation. Zhang et al. (2009) have shown that a G in position 118 is associated with reduced levels of the MOPr mRNA expression in Chinese hamster ovary cells expressing transfected variant forms of the receptor mRNA and that 118A mRNA was significantly more abundant than the 118G mRNA in human autopsy brain tissue from eight heterozygous subjects. This raises the interesting question of how a change in the gene sequence in the coding region of the gene might affect the levels of the expressed mRNA. Zhang et al. (2009) discuss the possibility that 118G causes reduced mRNA stability, but did not find an allele-specific impaired mRNA stability in transfected Chinese hamster ovary cells. Oertel et al. (2012) now offer an alternative explanation. They have shown that the A118G variant introduces a newly identified methylation site on the OPRM1 gene (the gene coding for MOPr) at nucleotide position 1117. The extent of methylation of the OPRM1 DNA at 1117 and at downstream methylation sites in DNA extracted from the brains obtained post mortem from heroin abusers (who died from an opiate overdose) and in controls, comparing methylation between the 118A and 118G alleles, was dependent on whether A or G was present at position 118. Significant increases in methylation (P , 0.05 or greater) were found at positions 1117, 1145, 1150, and 1159 in 118G-carrying heroin-abuser subjects, but were not observed in control subjects carrying the 118G allele. The significance of the altered methylation was evaluated by comparing the levels of MOPr mRNA expression in 118A and 118G carriers in both heroin abusers and control subjects. Heroin abusers carrying 118A exhibited significantly higher MOPr mRNA levels in two brain regions (thalamus and S11 cortex) than 118A controls, and an increase in the level of MOPr-binding sites; in contrast, heroin abusers with 118G (either one or two copies) expressed levels of MOPr mRNA and MOPr binding that were very similar to those of 118G controls in both brain regions. These results indicate that the presence of the 118G allele impairs the increased expression of MOPr mRNA that occurs when MOPr signaling efficiency is reduced after chronic opiate drug exposure. The sites showing increased methylation with the 118G allele include two predicted binding sites for the transcription factor Sp1 in OPRM1 DNA, providing a possible explanation for the reduced ability of chronic opiate drug users with the A118G polymorphism to increase MOPr RNA expression in response to impaired receptor signaling efficiency. The reason that increased OPRM1 DNA methylation was observed only in heroin-abuser 118G carriers but not in the 118G carrier controls is unexplained at this time. Nevertheless, it is clear that the A118G polymorphism occurring in a significant fraction of most populations modifies the regulation of MOPr expression and the sensitivity to the actions of opiate drugs. This study points to the complexity of the interaction of genetic, epigenetic, and environmental factors in the regulation of expression of the MOPr gene.
Concluding Thoughts
These recent developments in OPr research demonstrate that the research field in which Avram Goldstein played a prominent founding role 40 years ago is still very active. Increased understanding of the three-dimensional structure of all members of the OPr family will make it possible to design drugs with increased specificity for each receptor type and to address possible allosteric regulation of receptor function. We await with interest the determination of the threedimensional structures of the receptors when complexed with agonists and effector proteins. Improved understanding of how receptor expression and function is modified by primary sequence variations will contribute to our understanding of the differences between individuals in their responses to opiate drugs. Avram's seminal contributions to the development of this research field continue to bear fruit.
Authorship Contributions
Wrote or contributed to the writing of the manuscript: Cox
